First-in-human study evaluates dual-target, dual-payload ADC in advanced ovarian cancer and other solid tumours Phrontline ...
Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the ...
Singapore imaging provider is the earliest site in the region to adopt a new generation of MRI technology. MR31 will enable ...
Discontinuations by stated reason and by phase, APAC sponsors, 1 January to 30 September 2026. Source: BioPharma APAC ...
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over ...
Researchers will gain an integrated synthetic data foundation and an advanced custom search platform to support reaction data ...
Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure.
Hengrui Pharma announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready ...
Link Cell Therapies ("Link"), an oncology cell therapy company utilizing its proprietary logic-gating technology to develop ...
It has been evaluated across multiple clinical studies in patients with CLL/SLL who were either previously treated with a ...
NouvSight001 secures regulatory clearances from the US FDA and China’s NMPA for clinical development in retinitis pigmentosa, ...
The Stockholm Region deployment marks another important milestone in Lunit's expansion across Europe, demonstrating how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results